- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Biosensors for the detection of Alzheimer's disease (AD) biomarkers in a patient's blood or cerebrospinal fluid are known as Alzheimer's detection biosensors.
These biomarkers include tau proteins and amyloid beta (A) peptides, which are typical proteins identified in Alzheimer's patients' brains.
A substrate, a recognition component, and a transducer are the basic components of a biosensor. A molecule or a collection of molecules that can specifically bind to the target biomarker constitute the recognition element.
The recognition element's signal is transformed by the transducer into a quantifiable output, such as an electrical signal, an optical signal, or a mass change.
Surface plasmon resonance (SPR) biosensors, electrochemical biosensors, and optical biosensors are among the biosensors used to diagnose Alzheimer's disease.
Enzymes or antibodies are used by electrochemical biosensors to identify the biomarker and transform the signal into an electrical signal.
Optical biosensors produce a signal by detecting the biomarker with the help of light. The binding of the biomarker to the recognition element results in changes in refractive index, which SPR biosensors can detect.
The early identification and treatment of Alzheimer's disease could be revolutionised by Alzheimer's detecting biosensors.
Patients' quality of life can be enhanced by early detection and prompt treatment. Also, by using these biosensors, clinicians can use real-time monitoring to see how the disease is developing and how well a treatment is working.
Global Alzheimer's detection biosensor market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
A new biosensor being created by scientists from the Simon Fraser University (SFU) Nanodevice Fabrication Group will be used to screen for diseases like Alzheimer's and others. Their research has recently been summarised in the journal Nature Communications.
Their sensor functions by identifying a certain kind of tiny protein, in this case a cytokine called Tumour Necrosis Factor alpha (TNF alpha), which is connected to inflammatory processes in the body.
A wide range of illnesses, including Alzheimer's disease, malignancies, heart disease, autoimmune disorders, and cardiovascular disease, have all been associated with abnormal cytokine levels.
TNF alpha may serve as a biomarker, which is a quantifiable characteristic used to assess one's health.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.